News
- Author:
- Bruce Jancin
Publish date: September 26, 2018
PARIS – Phase 2 study on oral JAK inhibitors for alopecia areata yields promising data.
News
- Author:
- Bruce Jancin
Publish date: September 26, 2018
PARIS – The study was the first-ever phase 3 trial of a biologic in a pediatric atopic dermatitis population.
News
- Author:
- Bruce Jancin
Publish date: September 26, 2018
PARIS – Therapeutic benefits seen within first week.
News
- Author:
- Bruce Jancin
Publish date: September 25, 2018
PARIS – Topical anticholinergic pads show reassuring efficacy and safety in long-term extension study.
News
- Author:
- Bruce Jancin
Publish date: September 22, 2018
MUNICH – Secondary analysis of COMPASS trial hits pay dirt.
News
- Author:
- Bruce Jancin
Publish date: September 21, 2018
PARIS – Selectivity for just one of the three retinoic acid receptors results in less of the classic retinoid side effects.
News
- Author:
- Bruce Jancin
Publish date: September 19, 2018
PARIS – Selective tyrosine kinase 2 inhibitor reached a 75% PASI 75 response rate in moderate to severe psoriasis at 12 weeks.
News
- Author:
- Bruce Jancin
Publish date: September 18, 2018
MUNICH – New insights emerge from world’s biggest SCAD study.
News
- Author:
- Bruce Jancin
Publish date: September 14, 2018
PARIS – Oral vitamin B5 prolonged disease control following doxycycline discontinuation.
News
- Author:
- Bruce Jancin
Publish date: September 12, 2018
PARIS – Potentially practice-changing results of DEBUT trial.
News
- Author:
- Bruce Jancin
Publish date: September 11, 2018
CHICAGO – Expect reflectance confocal microscopy to take on a growing role in everyday dermatologic practice.
News
- Author:
- Bruce Jancin
Publish date: September 11, 2018
CHICAGO – Study shows melanomas of head and neck have numerous high-risk features for local recurrence.
News
- Author:
- Bruce Jancin
Publish date: September 10, 2018
MUNICH – POET trial shows early discharge after switch from intravenous to oral antibiotics is safe and effective...
News
- Author:
- Bruce Jancin
Publish date: September 10, 2018
ESTES PARK, COLO. – “The trick is not what drug you use, it’s what dose you started at” when treating anxiety dis...
News
- Author:
- Bruce Jancin
Publish date: September 4, 2018
MUNICH – Tafamidis is the first-ever disease-modifying therapy for this rapidly progressive and underdiagnosed form of cardiomyopathy.
